Hims & Hers: Novo Partnership Legitimizes but Margin Pressure Persists

What happened

The Novo Nordisk partnership has transformed Hims & Hers from a fringe obesity player into an official healthcare ecosystem participant, but the company's Q1 2026 results reveal the painful cost of that transformation: revenue grew only 4% year-over-year to $608 million, gross margin collapsed to 65% from 73%, and net income swung to a $92.1 million loss. Management's pivot away from high-margin compounded GLP-1s toward branded products forced $28.5 million in inventory write-downs and a shift to shorter shipping cadences that reduced monthly revenue per subscriber to $80 from $85. Despite the Novo tie-up, regulatory risk remains acute: Hims disclosed it was named in an FDA statement on restricting GLP-1 APIs and that HHS referred it to the DOJ for potential violations. With short interest still near 30% of the float, the stock trades as a binary bet on whether branded GLP-1 volumes can scale without further margin erosion or enforcement actions. Management's long-term targets of $6.5 billion revenue and $1.3 billion EBITDA by 2030 require sustained execution, but near-term gross margin guidance of additional 'couple of points' degradation suggests the pivot is far from complete.

Implication

The Novo partnership provides a channel for FDA-approved supply, but the pivot's costs are evident in Q1's margin compression and net loss. Hims must prove that branded GLP-1 volumes can grow beyond the initial 125,000 Wegovy shipments without further margin deterioration. Regulatory tail risk remains high given the DOJ referral and FDA statements, and that overhang is not diversified away. The current price of $24.20 sits between base case ($28) and bear case ($16), offering limited upside without confirmation of operating stability. Position sizing should reflect that any adverse enforcement action could quickly drive the stock toward the $16 bear case.

Thesis delta

The thesis shifts from 'compounded GLP-1 growth at high margins' to 'branded GLP-1 distribution at lower but potentially more durable margins with regulatory overhang.' The partnership reduces some legal risk but introduces execution risk on gross margin and subscriber monetization. The market's skepticism, reflected in high short interest, suggests the onus is on management to deliver tangible results in Q2 and Q3.